Role of HDL dysfunction in end-stage renal disease: a double-edged sword.
|
| Abstract |
End-stage renal disease (ESRD) is associated with a significant propensity for development of atherosclerosis and cardiovascular mortality. The atherogenic diathesis associated with ESRD is driven by inflammation, oxidative stress, and dyslipidemia. Reduced high-density lipoprotein cholesterol (HDL-C) level and high-density lipoprotein (HDL) dysfunction are the hallmarks of ESRD-related dyslipidemia. Clinical and laboratory studies have revealed that ESRD is associated with significantly reduced serum apolipoprotein A-I (ApoA-I) and HDL-C level as well as altered HDL composition. Furthermore, although ESRD is associated with impaired HDL antioxidant and anti-inflammatory properties in most patients, in a small subset, HDL may in fact have a pro-oxidant and proinflammatory effect. Therefore, it is no surprise that serum HDL-C level is not a dependable indicator of cardiovascular disease burden in ESRD, and markers such as HDL function are critical to accurately identifying patients at risk for cardiovascular disease and mortality in ESRD.
|
|---|---|
| Authors | Hamid Moradi, Nosratola D Vaziri, Moti L Kashyap, Hamid M Said, Kamyar Kalantar-Zadeh |
| Journal | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation (J Ren Nutr) Vol. 23 Issue 3 Pg. 203-6 (May 2013) ISSN: 1532-8503 [Electronic] United States |
| PMID | 23611547 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review) |
| Copyright | Copyright © 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!